Top View
- Partnerre Trigger Pharmaceuticals (At 9.3.20) Code Brand Name Generic Name Code Brand Name Generic Name J0800 Acthar®
- 761097Orig1s000
- CDER List of Licensed Biological Products With
- (INN) for Biological and Biotechnological Substances
- First-In-Human Study of Cemiplimab Alone Or in Combination with Radiotherapy And/Or Low Dose Cyclophosphamide in Patients with Advanced Malignancies
- Specialty Pipeline Monthly Update
- Myocarditis Occurrence with Cancer Immunotherapy Across Indications in Clinical Trial and Post‑Marketing Data Tigran Makunts1,2, Ila M
- PDF of Antibody News
- Specialty Medications - Medical Benefit
- The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights Into Novel Subsets Populating the Immune Microenvironment
- Immunotherapy Side Effects: Immune Checkpoint Inhibitors, 2020 1 About
- The State-Of-The-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies
- LIBTAYO 350 Mg Concentrate for Solution for Infusion
- Outpatient Drug Services Handbook
- Keytruda (Pembrolizumab) Usage in the Treatment of Cancer, Including FDA Approved Indications, and Off-Label Indications
- (Libtayo) for Cutaneous Squamous Cell Carcinoma
- 2020 Medicines in Development ꟷ Cancer
- Compilation of Abstract Titles from ASCO Annual Meeting 2021 (Oral, Poster Discussion, Posters, Mains Track by Cancer Types Only)
- Adult Cancers
- PD-(L)1 Inhibitors As Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: a Network Meta-Analysis
- Libtayo® (Cemiplimab-Rwlc)
- Moving up with the Monoclonals
- Infliximab: Remicade
- Cancer Immunotherapy: Successes and Pitfalls for the Non-Oncologist Daniel W
- A Case of New-Onset Vitiligo in a Patient on Tofacitinib and Brief Review of Paradoxical Presentations with Other Novel Targeted Therapies
- Drug Price Forecast Highlights July-August 2018 Executive Summary
- Medical Drug Benefit Clinical Criteria Updates
- Vaccination in Immunocompromised Patients ´Biologicals´
- For Health Professionals Who Care for Cancer Patients
- Comparative Efficacy and Safety of PD-1/PD-L1
- Policy: 200807-Mrx (07-20) Initial Effective Date: 12/01/2008
- Policy: 201101 Mrx Initial Effective Date: 02/17/2011
- Division of Research Activity Report
- Concurrent Therapy with Immune Checkpoint Inhibitors and Tnfα Blockade in Patients with Gastrointestinal Immune- Related Adverse Events Yousef R
- Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up Danny Rischin,1 Nikhil I
- Libtayo (Cemiplimab Rwlc)
- Medicare Part B PA List Effective 2021
- Crizanlizumab-Tmca
- Utilization Review Policy 133 LAST REVISED DATE
- Management of the Adverse Effects of Immune Checkpoint Inhibitors
- Clinical Criteria Updates for Specialty Pharmacy
- Actemra® (Tocilizumab)
- First-In-Human Study of Cemiplimab Alone Or in Combination with Radiotherapy And/Or Low Dose Cyclophosphamide in Patients with Advanced Malignancies
- Evaluation of Non-Clinical Requirements for Medicinal
- Partnerre Trigger Pharmaceuticals (At 03.20.19) Code Code Description Trade Name C9015 C-1 Esterase…………………….Haegarda® J3358 Ustekinumab Iv Inj, 1 Mg
- Phase 1 Cemiplimab Japanese Patients
- A CME/CE-Certified Supplement to Dermatology News
- Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors Per NCCN Guidelines with the Level of Evidence
- Publication Agenda CHMP 07-10 December 2020
- Durvalumab in Stage Iii Nsclc Case Presentation
- Related Adverse Events Due to Cancer Immunotherapy with Checkpoint
- LIBTAYO (Cemiplimab-Rwlc)
- Specialty Pipeline Monthly Update October 2018
- Reminder: Specific Medications Require Prior Authorization for Health Options
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- Dynamic Therapeutic Formulary Prior Authorization Drug List
- LIBTAYO Clinical Criteria
- Antibodies to Watch in 2018